HEPATOLOGÍA EXPERIMENTAL Y VECTORIZACIÓN DE FÁRMACOS
HEVEFARM
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (11)
2024
-
SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer
Cell Reports, Vol. 43, Núm. 3
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
-
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent
Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895
2022
-
Impact of alternative splicing variants on liver cancer biology
Cancers, Vol. 14, Núm. 1
-
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2020
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
-
Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach
Cancers, Vol. 12, Núm. 6, pp. 1-30
2019
-
The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis
Hepatology, Vol. 69, Núm. 4, pp. 1632-1647